MX2024003248A - Compuestos moduladores de gpr52. - Google Patents

Compuestos moduladores de gpr52.

Info

Publication number
MX2024003248A
MX2024003248A MX2024003248A MX2024003248A MX2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A MX 2024003248 A MX2024003248 A MX 2024003248A
Authority
MX
Mexico
Prior art keywords
sup
gpr52
modulating compounds
ameliorating
disclosures
Prior art date
Application number
MX2024003248A
Other languages
English (en)
Spanish (es)
Inventor
Michael Alistair O'brien
Nigel Alan Swain
Stephen Paul Watson
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Publication of MX2024003248A publication Critical patent/MX2024003248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024003248A 2021-09-15 2022-09-15 Compuestos moduladores de gpr52. MX2024003248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
MX2024003248A true MX2024003248A (es) 2024-04-02

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003248A MX2024003248A (es) 2021-09-15 2022-09-15 Compuestos moduladores de gpr52.

Country Status (22)

Country Link
US (1) US20240376070A1 (enExample)
EP (1) EP4401833B1 (enExample)
JP (1) JP2024535860A (enExample)
KR (1) KR20240058852A (enExample)
CN (1) CN117999258A (enExample)
AU (1) AU2022348201A1 (enExample)
CA (1) CA3232606A1 (enExample)
CL (1) CL2024000742A1 (enExample)
DK (1) DK4401833T3 (enExample)
ES (1) ES3053759T3 (enExample)
FI (1) FI4401833T3 (enExample)
GB (1) GB202113186D0 (enExample)
HR (1) HRP20251420T1 (enExample)
IL (1) IL311015A (enExample)
LT (1) LT4401833T (enExample)
MX (1) MX2024003248A (enExample)
PL (1) PL4401833T3 (enExample)
PT (1) PT4401833T (enExample)
RS (1) RS67399B1 (enExample)
SI (1) SI4401833T1 (enExample)
SM (1) SMT202500449T1 (enExample)
WO (1) WO2023041909A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
MX373876B (es) 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
CN111094278B (zh) * 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Also Published As

Publication number Publication date
WO2023041909A1 (en) 2023-03-23
IL311015A (en) 2024-04-01
SMT202500449T1 (it) 2026-01-12
CL2024000742A1 (es) 2024-09-27
US20240376070A1 (en) 2024-11-14
JP2024535860A (ja) 2024-10-02
PL4401833T3 (pl) 2026-02-16
LT4401833T (lt) 2025-12-10
DK4401833T3 (da) 2025-11-17
RS67399B1 (sr) 2025-11-28
ES3053759T3 (en) 2026-01-26
KR20240058852A (ko) 2024-05-07
HRP20251420T1 (hr) 2026-01-02
AU2022348201A1 (en) 2024-03-28
EP4401833B1 (en) 2025-10-22
EP4401833A1 (en) 2024-07-24
GB202113186D0 (en) 2021-10-27
PT4401833T (pt) 2025-11-14
SI4401833T1 (sl) 2026-01-30
CA3232606A1 (en) 2023-03-23
FI4401833T3 (fi) 2025-11-25
CN117999258A (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2022011333A (es) Compuestos moduladores de gpr52.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
EP4699655A3 (en) Compounds
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2022009308A (es) Compuestos y usos de estos.
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
PH12022551937A1 (en) Compounds and uses thereof
CL2024000742A1 (es) Compuestos moduladores de gpr52
MX2021012706A (es) Inhibidores de dihidroorotato deshidrogenasa.
BR112023003696A2 (pt) Compostos moduladores de gpr52
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
JOP20210050B1 (ar) معدلات تعبير pnpla3
MX369567B (es) ALCOHOLES TRIFLUOROMETILICOS COMO MODULADORES DE RORyT.
MX2022000811A (es) Inhibidores de enzimas.
CR20130055A (es) Compuestos aromáticos apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
WO2023129933A3 (en) 6,6-fused heterocyclic compounds as mettl3 inhibitors
PH12019501566B1 (en) Amide compounds and use thereof
JOP20230275A1 (ar) معدلات trex1
MX2022000165A (es) Moduladores del receptor alfa relacionado con estrogeno (err alfa ).
ES2051954T3 (es) 2-aminotiazoles substituidos.
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
WO2020074927A3 (en) Glp-1 receptor antagonists
MX417799B (es) Métodos para tratar trastornos mieloproliferativos